Public health and healthcare researchers need to understand not only how many people face barriers to Hepatitis C treatment, but also why those barriers delay care. The November 20, 2026 study in PLoS One shows how quantitative program data and qualitative interviews can work together to explain treatment access in Los Angeles County. This article examines the study through the lens of AI qualitative analysis of hepatitis C barriers, with practical guidance for researchers who need to synthesize interviews, identify themes, and compare experiences across language and treatment-status groups. The article also explains where AI can accelerate analysis while leaving interpretation, ethics, and clinical decisions with qualified research teams.
Run this analysis on your own data
Start freeKey Takeaways
The November 20, 2026 PLoS One study found that Hepatitis C treatment access in Los Angeles County was shaped by personal, provider-related, insurance, language, transportation, and healthcare-navigation barriers.
AI qualitative analysis can help public health teams organize interview transcripts, compare themes across treated and untreated participants, and connect qualitative explanations to quantitative barrier data, but researchers must validate AI-generated findings against the source material.
- Between October 2024 and January 2025, Los Angeles County program data covered 344 people with reported Hepatitis C-positive test results, including 168 people who had been treated and 176 who had not received treatment, according to the PLoS One study.
- The PLoS One study reported that 54% of the 344 case-residents experienced barriers, with personal barriers accounting for 43% of specific reported barriers, provider-related barriers for 31%, insurance barriers for 13%, and inadequate medical access for 13%.
- The qualitative sample in the PLoS One study included 10 interview participants between October 2024 and January 2025, including 7 untreated participants and 3 treated participants.
- The PLoS One study identified homelessness, incarceration, drug addiction, language barriers, long provider wait times, cost, transportation, limited information, and difficulty navigating healthcare as major barriers.
- The PLoS One study identified motivation, family and community support, provider trust, insurance coverage, understanding treatment benefits, and reducing stigma as facilitators of treatment access.
What the Hepatitis C Access Study Found
The PLoS One study used a convergent parallel mixed-methods design between October 2024 and January 2025, analyzing de-identified program data separately from semi-structured interviews before comparing the findings.
The quantitative analysis showed how frequently participants reported barriers, while the qualitative interviews explained how those barriers affected treatment decisions. The research team used descriptive frequencies and percentages for the program data because many specific barrier categories had fewer than 15 observations, and the team used iterative inductive coding for the interview transcripts.
The PLoS One researchers reported that personal and provider-related barriers were the most common categories. Interviews added context by showing how unstable housing, incarceration, substance use, language differences, unclear information, transportation problems, and fragmented referrals could make treatment difficult even after diagnosis.
Language and communication were especially important in the interviews. One untreated Spanish-speaking participant told the researchers, "Since I don’t speak 100% English... I didn’t understand very well what they were telling me, " describing how a Spanish-speaking primary care doctor later explained Hepatitis C more clearly.
The study also showed that treatment facilitators were relational as well as administrative. One treated participant said, "If they say this is a good idea, then I’m gonna do it, " illustrating how trust in a provider could support treatment decisions.
The study was exploratory and had important limitations. The PLoS One authors stated that the small qualitative sample, uneven distribution between treated and untreated participants, and absence of inferential analysis limit generalizability. The findings are research insights, not a clinical diagnosis or individual medical recommendation.
Hepatitis C Treatment Barriers: Findings Snapshot
| Date or period | Measure | Value | Research implication |
|---|---|---|---|
| October 2024 to January 2025 | Case-residents in program data | 344 | The quantitative dataset provided the scale of reported access barriers. |
| October 2024 to January 2025 | Case-residents already treated | 168, or 49% | Treatment status enabled comparison between treated and untreated people. |
| October 2024 to January 2025 | Case-residents without treatment | 176 | Untreated participants formed the larger program subgroup. |
| October 2024 to January 2025 | Case-residents reporting barriers | 54% | More than half of the program population reported at least one treatment-access barrier. |
| October 2024 to January 2025 | Specific barriers reported by category | Personal 43%; provider-related 31%; insurance 13%; inadequate medical access 13% | Barrier frequency indicates where programs can prioritize further investigation. |
| October 2024 to January 2025 | Qualitative interviews | 10 participants, 7 untreated and 3 treated | Interviews provided explanations and lived experience behind the quantitative categories. |
| 2019 to 2023 | People diagnosed with Hepatitis C in Los Angeles County | 27, 678 | The PLoS One study used this broader county context to describe the scale of the treatment-access challenge. |
| 2019 to 2023 | People reporting knowledge of Hepatitis C treatment | 30% | The study identified limited treatment knowledge as a relevant public health concern. |
| 2019 to 2023 | People completing Hepatitis C treatment | 32% | The study connected low completion with the need to address individual and system-level barriers. |
Implications for Public Health and Healthcare Researchers
How should researchers analyze language-related treatment barriers?
Researchers should analyze language-related barriers as both communication problems and healthcare-navigation problems. The PLoS One study found that Spanish-speaking participants described difficulty understanding providers, medication information, and treatment pathways, while also expressing a need for clearer provider guidance.
AI qualitative analysis can help researchers compare English- and Spanish-language transcripts after appropriate translation, preserve original quotations for review, and identify whether themes such as information gaps, mistrust, and provider frustration recur across language groups. Human researchers should verify translations and culturally sensitive interpretations.
How can mixed-methods teams connect counts with lived experience?
Mixed-methods teams can connect counts with lived experience by mapping quantitative categories to qualitative codes and then reviewing where the two data sources converge or differ. The PLoS One study used this approach to show that program data identified personal and provider barriers, while interviews explained the roles of homelessness, incarceration, addiction, cost, transportation, and communication.
A structured AI workflow can accelerate transcript coding, frequency analysis, and cross-segment comparisons, while researchers retain responsibility for code definitions, sampling decisions, contradictory evidence, and final interpretation.
What should care programs do with the findings?
Care programs should test interventions that address both individual and system-level barriers. The PLoS One authors highlighted language support, patient navigation, care coordination, mobile clinics for people experiencing homelessness, treatment continuity after incarceration, and fewer insurance restrictions as potential strategies.
Researchers can use follow-up interviews and open-ended surveys to evaluate whether these interventions improve understanding, trust, referral completion, and treatment initiation across language, insurance, housing, and treatment-status segments.
How Evidano Helps With AI Qualitative Analysis of Hepatitis C Barriers
Problem: Interview synthesis is slow across multiple participant groups
Evidano is an AI-powered qualitative data analysis platform that helps researchers analyze interviews, open-ended surveys, and documents.
Evidano can ingest interview transcripts and research documents, then support thematic, content, frequency, and cross-segment analyses. Researchers can compare treated and untreated participants or examine language, insurance, housing, and other segments without manually searching every transcript.
Researchers can review Evidano's AI qualitative analysis features alongside the original transcripts before finalizing themes.
Problem: Multilingual interviews can hide meaning during synthesis
Evidano supports transcription and translation workflows that can help research teams prepare English- and Spanish-language interview data for analysis. Custom dictionaries can improve consistency for specialized health terms, while researchers can retain the source-language material for quality checks.
Translation and AI-assisted coding should support, not replace, bilingual review, cultural interpretation, and participant-privacy safeguards.
Problem: Researchers need to move from themes to defensible evidence
Evidano provides AI chat over documents and analyses, plus visualizations such as word clouds, co-occurrence networks, and hierarchical codes and subcodes. These tools can help teams inspect relationships among themes such as cost, language, provider trust, and treatment motivation.
Evidano encrypts data and does not use customer data to train third-party models, which is relevant when researchers handle sensitive health interviews and de-identified program materials. Research teams should still follow their institutional review board requirements and approved data-management procedures.
FAQ: AI Qualitative Analysis of Hepatitis C Barriers
What were the main Hepatitis C treatment barriers in Los Angeles County?
+
The main barriers were personal circumstances, provider-related problems, insurance, inadequate medical access, language, transportation, limited information, and difficulty navigating healthcare, according to the PLoS One study published on November 20, 2026.
The study's quantitative data showed that personal barriers represented 43% of specific reported barriers and provider-related barriers represented 31%.
How many people participated in the Hepatitis C access study?
+
The study analyzed program data from 344 case-residents and interviewed 10 participants between October 2024 and January 2025.
The interview sample included 7 untreated participants and 3 treated participants, so the qualitative findings were exploratory rather than representative of every Los Angeles County resident with Hepatitis C.
How can AI help with qualitative Hepatitis C research?
+
AI can help researchers organize transcripts, identify recurring themes, compare participant segments, summarize evidence, and connect qualitative codes with quantitative categories.
AI-generated findings require human review because health research involves privacy, translation accuracy, cultural context, sampling limitations, and interpretive judgment.
What facilitators helped people access Hepatitis C treatment?
+
The PLoS One study identified personal motivation, family and community support, provider trust, adequate insurance, understanding treatment benefits, and the desire to avoid stigma as treatment facilitators.
These findings suggest that outreach should combine practical navigation with clear education, trusted provider communication, and support from family or community networks.
Can this study prove which intervention will eliminate treatment barriers?
+
No, the study cannot prove that a specific intervention will eliminate treatment barriers because its quantitative analysis was descriptive and its qualitative sample was small.
The PLoS One authors presented language support, patient navigation, mobile clinics, care continuity after incarceration, and reduced insurance restrictions as potential strategies requiring further evaluation.
Conclusion and Next Steps
The November 20, 2026 PLoS One study demonstrates why public health teams need both quantitative measures and qualitative explanations to understand Hepatitis C treatment access. AI qualitative analysis can make large collections of interviews, surveys, and research documents easier to code, compare, and review, while researchers remain accountable for interpretation and ethics. For teams studying healthcare access, multilingual communication, and treatment navigation, Evidano can provide a structured environment for moving from raw narratives to defensible themes. Try Evidano for free to analyze qualitative research data more efficiently.
Topics
- qualitative analysis of hepatitis C barriers
- AI qualitative research healthcare
- hepatitis C treatment access barriers
- mixed-methods health research
- thematic analysis public health
Run this analysis on your own data
Evidano codes documents, interviews, survey responses and spreadsheets with AI, with your judgment in control at every step.
Keep reading
- Commentary on NewsContext Matters: Qualitative Analysis in Hypertension ResearchLearn how qualitative analysis in hypertension research reveals stress, coping, and social support patterns, with AI tools for faster, safer synthesis.
- Commentary on NewsAI Qualitative Analysis in Healthcare: SYNC-RFSee how AI qualitative analysis in healthcare synthesizes interviews, surveys, and facility data for continuity-of-care research. Explore Evidano today.
- Commentary on NewsSmarter Care Insights: AI Thematic Analysis in HealthcareSee how AI thematic analysis in healthcare can support mixed-methods research, referral studies, and faster synthesis of complex patient interviews.
